K6S.F MIRA Pharmaceuticals, Inc.
- Market cap
- EUR 22.9M
- P/E
- -
- P/B
- 3.06x
- ROE
- -57.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is K6S.F undervalued?
Graham numberThe Graham number of MIRA Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MIRA Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for MIRA Pharmaceuticals, Inc. yet.
MIRA Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering fr…
Full company profileMIRA Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MIRA Pharmaceuticals, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.15M | -7.05M | -8.53M | -8.02M | -10.5M | -4.52M |
| EBITDA | - | -7.05M | -8.53M | -8.02M | -10.5M | -4.52M |
| Net Income | -2.18M | -7.06M | -12.0M | -7.85M | -10.4M | -4.72M |
| EPS | -0.15 | -0.48 | -0.81 | -0.47 | -0.25 | -0.11 |
| Balance Sheet | ||||||
| Total Assets | 3.36M | 858K | 4.93M | 2.92M | 11.1M | 8.20M |
| Total Liabilities | 1.09M | 1.45M | 558K | 723K | 702K | 40.8K |
| Shareholders' Equity | 2.26M | -596K | 4.37M | 2.20M | 10.4M | 8.16M |
| Cash & Short-term Investments | 2.81M | 351K | 4.60M | 2.83M | 6.35M | 3.61M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.38M | -5.60M | -4.53M | -5.56M | -4.66M | -4.81M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.38M | -5.60M | -4.53M | -5.56M | -4.66M | -4.81M |
| Ratios | ||||||
| ROE | -96.2% | - | -273.9% | -357.0% | -100.5% | -57.8% |
| ROA | -64.9% | -822.6% | -242.9% | -268.6% | -94.1% | -57.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
MIRA Pharmaceuticals, Inc. dividends
MIRA Pharmaceuticals, Inc. has not paid dividends in the last 5 fiscal years.
Who owns MIRA Pharmaceuticals, Inc.
- Insiders 30.58%
- Institutions 5.79%
- Public & others 63.63%
- Shares outstanding 42.0M
- Free float 38.7M
MIRA Pharmaceuticals, Inc. company profile
- Company name
- MIRA Pharmaceuticals, Inc.
- Ticker
- K6S.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Fiscal year end
- December
- Address
- 1200 Brickell Avenue, Miami, FL, United States, 33131
- Phone
- 786 432 9792
- Website
- mirapharmaceuticals.com
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
MIRA Pharmaceuticals, Inc. management
3- Mr. Erez AminovCEO & Chairman · born 1978
- Mr. Andriy Mushak CPAChief Financial Officer · born 1983
- Dr. Itzchak Angel Ph.D.Chief Scientific Advisor